Cargando…

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

BACKGROUND: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Fateen, Waleed, Khan, Farooq, O’NeiSSll, Richard J, James, Martin W, Ryder, Stephen D, Aithal, Guruprasad P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652915/
https://www.ncbi.nlm.nih.gov/pubmed/29082223
http://dx.doi.org/10.2147/JHC.S144068
_version_ 1783273150735187968
author Fateen, Waleed
Khan, Farooq
O’NeiSSll, Richard J
James, Martin W
Ryder, Stephen D
Aithal, Guruprasad P
author_facet Fateen, Waleed
Khan, Farooq
O’NeiSSll, Richard J
James, Martin W
Ryder, Stephen D
Aithal, Guruprasad P
author_sort Fateen, Waleed
collection PubMed
description BACKGROUND: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare health-care costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK. METHODS: Using a dedicated radiology database, we identified all patients who had undergone cTACE or DEB-TACE between 2006 and 2012 at a single tertiary referral center based in Nottingham. We collected clinical data, including treatment response, postprocedure complications and 30-day mortality. Costing models were constructed to present both our local hospital perspective as well as the national health service position. RESULTS: During our study period, 101 procedures were performed on 43 patients (76 cTACE procedures on 26 patients and 25 DEB-TACE procedures on 17 patients). Overall, 11/26 in cTACE and 5/17 in DEB-TACE group had progressive disease (p=0.52). Adverse events were seen in 6/76 cTACE compared with 7/25 DEB-TACE group (p=0.16). Based on the predetermined standard pathway there was an unadjusted average cost difference of £3770.30 (TACE =£9070.44, DEB-TACE =£5300.14) in favor of the DEB-TACE. Results from our costing models indicated a £2715.33 (95% CI £580.88–4849.77) cost difference in favor of the same procedure. CONCLUSIONS: Even when the extra costs of DEB-TACE were considered, the overall treatment costs per patient were lower in relation to cTACE.
format Online
Article
Text
id pubmed-5652915
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56529152017-10-27 Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma Fateen, Waleed Khan, Farooq O’NeiSSll, Richard J James, Martin W Ryder, Stephen D Aithal, Guruprasad P J Hepatocell Carcinoma Original Research BACKGROUND: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare health-care costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK. METHODS: Using a dedicated radiology database, we identified all patients who had undergone cTACE or DEB-TACE between 2006 and 2012 at a single tertiary referral center based in Nottingham. We collected clinical data, including treatment response, postprocedure complications and 30-day mortality. Costing models were constructed to present both our local hospital perspective as well as the national health service position. RESULTS: During our study period, 101 procedures were performed on 43 patients (76 cTACE procedures on 26 patients and 25 DEB-TACE procedures on 17 patients). Overall, 11/26 in cTACE and 5/17 in DEB-TACE group had progressive disease (p=0.52). Adverse events were seen in 6/76 cTACE compared with 7/25 DEB-TACE group (p=0.16). Based on the predetermined standard pathway there was an unadjusted average cost difference of £3770.30 (TACE =£9070.44, DEB-TACE =£5300.14) in favor of the DEB-TACE. Results from our costing models indicated a £2715.33 (95% CI £580.88–4849.77) cost difference in favor of the same procedure. CONCLUSIONS: Even when the extra costs of DEB-TACE were considered, the overall treatment costs per patient were lower in relation to cTACE. Dove Medical Press 2017-10-16 /pmc/articles/PMC5652915/ /pubmed/29082223 http://dx.doi.org/10.2147/JHC.S144068 Text en © 2017 Fateen et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Research
Fateen, Waleed
Khan, Farooq
O’NeiSSll, Richard J
James, Martin W
Ryder, Stephen D
Aithal, Guruprasad P
Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
title Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
title_full Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
title_fullStr Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
title_full_unstemmed Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
title_short Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
title_sort healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652915/
https://www.ncbi.nlm.nih.gov/pubmed/29082223
http://dx.doi.org/10.2147/JHC.S144068
work_keys_str_mv AT fateenwaleed healthcarecostsoftransarterialchemoembolizationinthetreatmentofhepatocellularcarcinoma
AT khanfarooq healthcarecostsoftransarterialchemoembolizationinthetreatmentofhepatocellularcarcinoma
AT oneissllrichardj healthcarecostsoftransarterialchemoembolizationinthetreatmentofhepatocellularcarcinoma
AT jamesmartinw healthcarecostsoftransarterialchemoembolizationinthetreatmentofhepatocellularcarcinoma
AT ryderstephend healthcarecostsoftransarterialchemoembolizationinthetreatmentofhepatocellularcarcinoma
AT aithalguruprasadp healthcarecostsoftransarterialchemoembolizationinthetreatmentofhepatocellularcarcinoma